28
Feb
Sanofi India Limited (SIL) reported steady growth in Q4 2024, with revenue growing 9.7% year-on-year (YoY) to ₹514.9 crore, compared to ₹469.2 crore in the same quarter last year. EBITDA grew 18.8% year-on-year to ₹118.3 crore, from ₹99.6 crore. Operating margins also improved to 23%, compared to 21.2% in Q4 2023. However, the company's net profit declined 33.7% to ₹91.3 crore, from ₹137.7 crore a year ago. On the bright side, the board has recommended a final dividend of ₹117 per equity share of ₹10 face value, subject to shareholders' approval at the forthcoming Annual General Meeting. Sanofi India's recent…